Reuters Health Report

Click to View in Browser 03/18/2014 Rivals race to develop new biotech asthma drugs LONDON (Reuters) - Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion. FDA delays decision on Biogen's multiple sclerosis drug (Reuters) - Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application. Unease grows among U.S. doctors over Indian drug quality WASHINGTON/NEW YORK (Reuters) - Some U.S. doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration. Croatia merges hospitals, cuts beds in healthcare masterplan ZAGREB (Reuters) - Croatia, struggling to reduce a shortfall in its public finances, plans to merge two-thirds of state-run hospitals and cut the number of beds by 2017 in an effort to put its ailing health sector on a solid footing. Europe failing to tackle drug-resistant tuberculosis LONDON (Reuters) - Cases of tuberculosis are falling in Europe but a failure to properly diagnose and treat dangerous drug-resistant strains of the contagious disease means it is far from under control, health experts said on Tuesday. France's Ipsen says Dysport incontinence treatment trial positive PARIS (Reuters) - French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence. Israel's Gamida Cell gets buyout offer from unnamed drugmaker JERUSALEM (Reuters) - Israeli developer of stem cell therapies Gamida Cell has received a buyout offer worth hundreds of millions dollars from an unnamed global pharmaceutical company, two shareholders in the company said on Tuesday. ThromboGenics reports slowdown of sales of main drug Jetrea BRUSSELS (Reuters) - Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of 2013. A plunge in U.S. preschool obesity? Not so fast, experts say NEW YORK (Reuters) - If the news last month that the prevalence of obesity among American preschoolers had plunged 43 percent in a decade sounded too good to be true, that's because it probably was, researchers say. Mothers' monitoring of media tied to kids' weight NEW YORK (Reuters Health) - Children whose mothers pay close attention to how much time they spend watching TV and playing video games tend to weigh less, according to a new study. Related Video World's longest aircraft takes disaster relief to new heights Washington hit with late season snow The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend